The bioavailability of coenzyme Q10 supplements available in New Zealand differs markedly [1]

New Zealand Medical Journal

Volumn 117, Issue 1203, 2004, Pages

  Molyneux, Sarah ^a   Florkowski, Christopher ^b   Lever, Michael ^b   George, Peter ^b  

^a UNIVERSITY OF CANTERBURY   (New Zealand)

^b CANTERBURY HEALTH LABORATORIES   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BLACKMORES; GOOD HEALTH; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KORDEL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; Q GEL; RADIANCE; SOLGAR; THOMPSON; UBIDECARENONE;

ADULT; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG MECHANISM; DRUG SOLUBILITY; DRY POWDER; FOOD COMPOSITION; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; LETTER; MALE; NEW ZEALAND; NORMAL HUMAN; NUTRITIONAL DEFICIENCY; OXIDATIVE STRESS; PARKINSON DISEASE; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION;

EID: 27244460578     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Letter

References (12)

1. Sohal RS. Coenzyme Q and vitamin E interactions. Meth Enzymol. 2004;378:146-51.
2. Weber C, Bysted A, Høolmer G. The Coenzyme Q10 content of the average Danish diet. Internat J Vit Nutr Res. 1997;67:123-9.
3. Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMGCoA reductase inhibitors: A double-blind, placebo-controlled study. J Clin Pharmacol. 1993;33:226-9.
4. Miles MV, Horn P, Miles L, et al. Bioequivalence of coenzyme Q10 from over-the-counter supplements. Nutr Res. 2002;22:919-29.
5. Chopra RK, Goldman R, Sinatra ST, Bhagavan HN. Relative bioavailability of coenzyme Q10 formulations in Human subjects. Internat J Vit Nutr Res. 1998;68:109-13.
6. Walhlqvist ML, Wattanapenpaiboon N, Savige GS, Kannar D. Bioavailability of two different formulations of coenzyme Q10 in healthy subjects. Asia Pac J Clin Nutr. 1998;7:37-40.
7. Tang PH, Miles MV, DeGrauw A, et al. HPLC analysis of reduced and oxidised coenzyme Q10 in human plasma. Clin Chem 2001;47:256-65.
8. Niklowitz P, Menke T, Andler W, Okum JG. Simultaneous analysis of coenzyme Q10 in plasma, erythrocytes and platelets: comparison of the antioxidant level in blood cells and their environment in healthy children and after oral supplementation in adults. Clin Chim Acta. 2004;342:219-26.
9. Feigin A, Kieburtz K, Como P, et al. Assessment of Coenzyme Q10 Tolerability in Huntington's Disease. Mov Disord. 1996;11:321-3.
10. Weis M. Mortensen SA. Rassing MR, et al. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. Mol Aspects Med. 1994;15:S273-S80.
11. Kaikkonen J, Nyyssönen K, Porkkala-Sarataho E, et al. Effect of oral coenzyme Q10 supplementation on the oxidation resistance of human VLDL + LDL fraction: Absorption and antioxidative properties of oil and granule-based preparations. Free Radic Biol Med. 1997;22:1195-202.
12. Kurowska EM, Dresser G, Deutsch L, et al. Relative bioavailability and antioxidant potential of two coenzyme Q10 preparations. Ann Nutr Metab. 2003;47:16-21.